Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensifi-cation. Among 901 patients under age 21 years, 5-year survival w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lange, Beverly J., Smith, Franklin O., Feusner, James, Barnard, Dorothy R., Dinndorf, Patricia, Feig, Stephen, Heerema, Nyla A., Arndt, Carola, Arceci, Robert J., Seibel, Nita, Weiman, Margie, Dusenbery, Kathryn, Shannon, Kevin, Luna-Fineman, Sandra, Gerbing, Robert B., Alonzo, Todd A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2008
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214754/
https://ncbi.nlm.nih.gov/pubmed/18000167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-084293
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge